Investment Rating - The report maintains a positive investment outlook for the polyester sector, particularly recommending high-quality companies in the polyester filament and bottle chip segments [6][13]. Core Insights - The report highlights that the cost support for polyester filament remains solid, with expectations for inventory replenishment post-holiday. The operating rate of polyester filament has significantly decreased, laying a foundation for recovery after the Spring Festival [6][7]. - Polyester filament inventory has been consistently declining since the beginning of 2026, with downstream textile raw material inventory also at low levels, indicating a strong demand for replenishment after the holiday [7][11]. - The price spread of polyester filament has improved significantly, with cost support expected to remain strong due to stable raw material prices and proactive supply adjustments [11][13]. Summary by Sections Supply and Demand Dynamics - The operating rate of polyester filament has dropped to 79.65%, down approximately 16 percentage points from previous highs, as companies conduct maintenance ahead of the holiday [6]. - Downstream textile operating rates have fallen to 25.15%, marking a low for the year, which is expected to lead to a rigid demand for inventory replenishment post-holiday [6][7]. Price Trends - As of February 6, 2026, the price spreads for polyester filament POY, FDY, and DTY are 1375, 1575, and 2475 CNY/ton respectively, indicating a recovery in price spreads since late January 2026 [11]. - The PTA price, a key raw material for polyester filament, remains high, with limited downward pressure expected, providing solid support for filament prices throughout the year [11][13]. Company Recommendations - The report recommends focusing on high-quality companies in the polyester filament sector such as Tongkun Co., Ltd. and in the bottle chip sector like Wankai New Materials. It also suggests monitoring leading refining companies such as Hengli Petrochemical and Rongsheng Petrochemical due to expected improvements in cost structures [13][15].

Report Summary 1. Report Industry Investment Rating No industry investment rating is provided in the report. 2. Core Viewpoints - FINQ issued two high - concentration AI ETFs last week in the US, with unique investment strategies [2][8]. - In the past week, US domestic stock ETFs had an inflow of nearly $30 billion, while international stock and bond products had outflows [2][10]. - This year, US market volatility has been high, and long - volatility products related to the VIX index have performed well [2][13]. - In December 2025, the total non - money mutual funds in the US decreased, and from January 21 to 28, domestic stock funds had outflows, international stock product outflows expanded, and bond product inflows increased [2][17]. 3. Summary by Directory 3.1 US ETF Innovation Products: FINQ Issues High - Concentration AI ETF - Last week, there were 18 new ETF products in the US, and single - stock products had a new strategy type. GraniteShares launched new single - stock snowball products, with a potential annualized snowball return of 17.83% for the NVIDIA - linked product. NEOS issued a series of accelerated high - yield ETFs, and Tuttle Capital launched a UFO - related product [7][8]. - FINQ issued two AI ETFs. The FINQ FIRST US Lg Cap AI - Mgd Equity ETF invests in 13 - 16 stocks with the highest scores from an AI model, and the market - neutral ETF holds about 10 stocks with the highest and lowest scores respectively [2][8]. 3.2 US ETF Dynamics - **US ETF Funds: International Stock and Bond Products Have Outflows** - In the past week, US domestic stock ETFs had an inflow of nearly $30 billion, while international products and international bond products had outflows. The Nasdaq ETF had outflows again, Vanguard's S&P 500 ETF had a stable inflow, and BlackRock's small - cap products had an inflow. In the precious metals market, silver ETFs had an inflow and gold ETFs had an outflow. High - yield bonds had outflows, and investment - grade bond products had inflows [2][10][12]. - **US ETF Performance: VIX Index - Related Products Have Top - Ranked Gains** - This year, due to high market volatility in the US, long - volatility products have performed well. For example, the 2x long - term VIX index product has a gain of over 15%, and short - term VIX index products have a gain of over 10% [2][13]. 3.3 Recent US Ordinary Mutual Fund Fund Flows - In December 2025, the total non - money mutual funds in the US were $23.64 trillion, a decrease of $0.09 trillion from November 2025. The S&P 500 fell 0.05% in December, and the scale of domestic stock products decreased by 1.03%. - From January 21 to 28, domestic stock funds had an outflow of $12.849 billion, international stock product outflows expanded to $5 billion, and bond product inflows expanded to $16.7 billion [2][17].

Investment Rating - The report rates the defense and military industry as "Overweight" indicating an expectation for the industry to outperform the overall market [2][3]. Core Insights - The report highlights that the order transmission is orderly, and an inflection point in performance is anticipated. A selection of 55 key companies in the military industry chain is expected to achieve a total net profit of approximately 10.15 billion yuan in Q4 2025, representing a year-on-year increase of 99.7%, and a total net profit of about 27.67 billion yuan for the year 2025, reflecting a year-on-year growth of 8.7% [3]. - Performance across different segments is expected to vary due to customer structure and revenue recognition timing. For instance, the electronic components segment is projected to see significant growth in companies like Zhenhua Technology and Hongda Electronics, while high-end materials may experience mixed results [3]. - The report emphasizes the importance of the 14th Five-Year Plan and the upcoming 15th Five-Year Plan, which aim to enhance the quality and modernization of the military, suggesting that the military industry will enter a new cycle of quality improvement and growth [3]. - The report suggests maintaining a high level of attention to the military industry as it enters the 15th Five-Year Plan period, with expectations for continued improvement in fundamentals and order delivery [3]. - Investment opportunities are identified in both domestic demand growth and emerging fields driven by technological advancements, including areas such as military trade, commercial aerospace, and deep-sea technology [3]. Summary by Sections Key Companies and Performance Forecast - The report lists key companies and their expected performance for Q4 2025 and the full year 2025, with notable growth rates in various segments. For example, Zhenhua Technology is expected to grow by 17.3% in Q4 2025, while companies like Chengdu Huami and Unisoc are projected to see growth rates of 395.1% and 171.7%, respectively [4][5]. - The report provides a detailed table of expected profits for various companies, indicating significant growth potential in the military industry [4][6]. Investment Focus Areas - The report identifies specific companies to watch, including AVIC Shenyang Aircraft Corporation, Feilihua, and Unisoc for domestic demand, and companies like Ruichuang Micro-Nano and Aerospace Electronics for external growth opportunities [3]. - It highlights the importance of technological advancements and the evolving landscape of military needs, suggesting that companies involved in smart technology and unmanned systems will be key players in the future [3].

Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a positive outlook for its stock performance relative to the market [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, reflecting a year-on-year growth of 21.8%, and a net profit attributable to shareholders of 237 million yuan, up 33.9% [5][8]. - In Q4 2025, the company achieved a revenue of 262 million yuan, a 21.5% increase year-on-year, and a net profit of 78 million yuan, which is a 26.4% increase [5][8]. - The company is expanding its generic drug product line while simultaneously advancing its new drug development, with a focus on cost reduction and efficiency improvements [5][8]. Financial Data and Profit Forecast - The company’s total revenue is projected to be 1.171 billion yuan in 2026, with a slight decrease to 1.110 billion yuan in 2027 [7]. - The net profit forecast for 2025 is 237 million yuan, followed by 174 million yuan in 2026 and 140 million yuan in 2027, indicating a decline in profitability in the following years [7][9]. - The company’s gross margin is expected to decrease from 83.4% in 2025 to 71.6% in 2027, reflecting potential pricing pressures from market competition [7]. Generic Drug Business - The sales of core products such as "复瑞彤" and "波开清" are steadily increasing, driving growth for the company [8]. - The company is proactively expanding its portfolio of generic drugs, with eight new drug registration approvals obtained in 2025 [8]. Innovative Drug Business - The company is advancing its pipeline of innovative drugs, with the DYX116 project progressing as expected, having completed Phase I clinical trials [8]. - The market for GLP-1 drugs in China is projected to reach 609 billion yuan by 2030, indicating significant growth potential for the company’s innovative drug offerings [8].

Investment Rating - The report maintains a positive outlook on the defense and military industry, recommending continued focus on commercial aerospace and large aircraft sectors [4][5]. Core Insights - The defense and military industry is expected to see a recovery in performance and orders, with a trend of acceleration anticipated in the second quarter of 2026. Increased military spending intentions from Europe and the US, along with potential catalysts from the upcoming Two Sessions military budget, suggest a sustained interest in the military sector [4]. - The report indicates that the military industry is entering a new cycle of quality improvement and growth, driven by the 14th Five-Year Plan and ongoing geopolitical tensions [4]. - The commercial aerospace sector is highlighted as a key area for investment, with significant developments expected in reusable spacecraft technology and a focus on nearly 30 launch missions in 2026 [4]. - The report emphasizes investment opportunities driven by domestic demand growth and technological advancements in the military sector, including areas such as smart technology, unmanned systems, and military trade [4]. Market Performance - Last week, the Shenwan Defense and Military Index rose by 0.21%, while the CSI Military Leaders Index increased by 0.6%. In contrast, the Shanghai Composite Index fell by 1.27%, and the ChiNext Index dropped by 3.28%, indicating that the defense sector outperformed the broader market indices [5][12]. - The top five performing stocks in the defense sector included Shenjian Co. (up 28.07%), Galaxy Electronics (up 21.58%), and TeFa Information (up 20.17%), while the bottom five performers included Tongyou Technology (down 18.37%) and Chunxing Precision (down 13.65%) [12][13]. Valuation Changes - The current PE-TTM for the Shenwan military sector is 95.29, indicating it is in the upper range historically, with a valuation percentile of 74.63% since January 2014 [12][21]. - The report notes a differentiation in valuations among sub-sectors, with aerospace and aviation equipment showing relatively high PE valuations since 2020 [12][21].

Group 1 - The report indicates that the overseas technology stocks have experienced significant adjustments, which may release risks and suggests a potential recovery in market sentiment before the holiday [1][6][7] - The North Exchange 50 index fell by 0.7%, with trading volume decreasing by 28.7%. The market showed considerable volatility, particularly influenced by the "Wosh trading" on Monday, leading to a notable decline [6][10] - Certain sectors such as food and beverage, beauty care, transportation, and banking performed relatively well due to their low valuation and growth rates, while the power equipment sector was more volatile due to themes related to space photovoltaic [6][10] Group 2 - The report highlights that the North Exchange's PE (TTM) average is 82.05 times, with a median of 39.37 times, indicating a decline in valuation metrics [10][12] - The trading volume for the North Exchange was 4.218 billion shares, a decrease of 29.24% week-on-week, and the total trading amount was 102.42 billion yuan, down 28.70% [10][17] - The report notes that 63 stocks rose while 224 stocks fell, resulting in a rise-to-fall ratio of 0.28, with *ST Yunchuang and Optec leading the gains [26][28] Group 3 - The report mentions that the upcoming week will see the listing of Aide Technology, with no new stocks listed this week. As of February 6, 2026, there are 292 companies listed on the North Exchange [19][39] - The report identifies specific stocks to watch due to potential mispricing from reduced risk appetite, including Liancheng CNC, Gebijia, Kaide Quartz, and others [7][26][39]

Quantum Technology - The team from the University of Science and Technology of China achieved significant breakthroughs in scalable quantum networks, including the construction of a basic module for scalable quantum repeaters, which realized an entanglement lifetime of 550 milliseconds, surpassing the establishment time of 450 milliseconds, thus overcoming a core bottleneck in quantum network expansion [4][5] - The team also achieved device-independent quantum key distribution (DI-QKD) over a 100-kilometer fiber link, improving the distance by over 100 times compared to previous best experimental levels, marking a milestone in quantum communication and expanding China's international leading position in this field [4][5] Biomanufacturing - The Shenzhen Advanced Institute of Technology developed a programmable integration platform for functional molecules, enabling applications in biomanufacturing, biosensing, and flexible electronics. This platform combines metabolic sugar engineering with click chemistry, allowing for precise covalent integration of various functional molecules [6][7] - OpenAI partnered with Ginkgo Bioworks to create an AI-driven automated experimental system that reduced the production cost of cell-free protein synthesis (CFPS) by approximately 40% and reagent costs by 57% [8] Hydrogen Energy and Nuclear Fusion - The Zhongneng Construction's Songyuan Hydrogen Energy Industrial Park project has produced over 10,000 tons of green ammonia and received EU certification, validating the integrated commercial loop of green electricity, green hydrogen, and green ammonia [9][10] - Shenzhen University's team achieved important breakthroughs in the preparation of key materials and components for fusion reactors, mastering mature technology for the first wall of fusion reactors, which will support domestic fusion reactor construction and development [10] Brain-Computer Interface - Borui Kang initiated the listing guidance process, marking a shift from research investment to market expansion for brain-computer interface technology. The company’s NEO product has completed over 32 implant surgeries with no adverse reactions, demonstrating the safety and feasibility of its minimally invasive implantation method [12][14] - Research from the Chinese Academy of Sciences established a new optogenetic technology for visual brain-computer interfaces, allowing for high-precision, long-term optical stimulation of the visual cortex, representing a significant advancement in sensory information input technology [15][17] Embodied Intelligence - Microsoft Research released a new robot model, Rho-alpha, which integrates multimodal perception capabilities, including visual, language, and tactile data, aimed at enhancing the application of embodied intelligence in unstructured environments [19] 6G and Commercial Space - The Beijing University of Posts and Telecommunications made significant progress in 6G channel modeling, with their model being included in the international 6G standard system by 3GPP [20] - The FCC accepted SpaceX's application for an orbital data center, which aims to create a satellite constellation of up to 1 million satellites to support advanced AI models and applications, indicating rapid regulatory progress [22]

Investment Rating - The report maintains a positive outlook on the pet food industry, highlighting the continued growth and resilience of leading brands in the market [3][5]. Core Insights - The pet food industry is experiencing a consumption upgrade driven by product innovation and changing consumer demands, with a notable shift towards high-end and functional pet food products [3][5]. - The market is witnessing a significant concentration of leading brands, with top players expanding their market share amidst increasing competition [5][3]. - The aging pet population in China is expected to further drive demand for specialized and high-quality pet food products [5][3]. Long-term Trends - The report indicates that the number of new pet owners is expected to grow, supported by a stable increase in the population of young adults aged 20-35, who are the primary pet owners [4][12]. - The pet population in urban areas is projected to continue increasing, with dog and cat numbers reaching 53.43 million and 72.89 million respectively by 2025, reflecting a year-on-year growth of 1.6% and 1.9% [12][4]. Mid-term Trends - Product innovation is leading to a consumption upgrade, with mid to high-end price segments (60-100 RMB/kg) showing significant growth rates compared to lower price segments [3][28]. - The report notes that the demand for specialized pet food, including functional and prescription diets, is on the rise as pet owners become more aware of their pets' nutritional needs [5][45]. Short-term Trends - The pet food industry is expected to maintain strong growth, with online sales projected to reach 30.71 billion RMB in 2025, reflecting a year-on-year increase of 10.2% [5][3]. - The concentration of market share among top brands is increasing, with the top five brands accounting for 25.3% of the market, indicating a trend towards fewer but stronger players in the industry [5][3]. Future Outlook - The report anticipates that the trend towards consumption upgrades will continue, with high-end and functional pet food products leading the market [5][3]. - The increasing recognition of brand quality and the aging pet population are expected to enhance the market share of foreign brands, particularly in the prescription food segment [5][3]. - The report highlights that product innovation will be crucial for companies to differentiate themselves in a competitive market, with functional and prescription diets likely to become the next growth drivers [5][3].

Investment Rating - The report maintains an "Overweight" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating a positive outlook for the industry compared to the overall market performance [1][4]. Core Insights - The total net profit for the tracked companies in the agricultural, forestry, animal husbandry, and fishery sector is projected to be CNY 30.949 billion for 2025, reflecting a year-on-year decrease of 20%. The top three sub-sectors by profit growth are animal health (+76%), planting industry (+54%), and pet food (+3%) [3][4]. - The report highlights significant performance disparities among different sectors, with the animal husbandry sector facing challenges due to oversupply and declining prices, particularly in pig farming, where the average price of pigs dropped by 29.9% year-on-year [3][5]. - The pet food sector shows resilience in domestic markets despite a slowdown in overseas growth, with a projected online sales growth of 10.2% in 2025 [3][4]. Summary by Relevant Sections Animal Husbandry - The pig farming sector is expected to see a net profit of CNY 20.908 billion in 2025, down 26% year-on-year, with significant losses reported in Q4 [5][8]. - The chicken farming sector remains profitable, with white chicken prices stable and yellow chicken prices showing a 9.5% increase year-on-year [3][4]. Pet Food - Domestic pet food sales are projected to grow, with major companies like Guobao Pet and Zhongchong Co. expected to report net profits of CNY 0.678 billion and CNY 0.433 billion, respectively [3][4]. Planting Industry - The report notes a recovery in edible mushroom prices, with a projected net profit increase of 154% for Zhongxing Junye in 2025 [3][4]. - Blueberry prices have slightly decreased, but companies are expected to maintain profitability through volume sales [3][4]. Animal Health - The animal health sector is projected to see a net profit increase of 76%, driven by new product launches and increased demand for veterinary vaccines [3][4]. Seed Industry - The seed industry is facing challenges with low grain prices, leading to a mixed performance among companies, with Dabeinong expected to report a significant loss [3][4].

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, particularly highlighting the high-quality development plan for traditional Chinese medicine [2][11]. Core Insights - The pharmaceutical sector's overall performance shows a slight increase, with the Shenwan Pharmaceutical and Biological Index rising by 0.14%, while the Shanghai Composite Index fell by 1.27% [3][2]. - The report emphasizes the implementation of the "High-Quality Development Implementation Plan for Traditional Chinese Medicine Industry (2026-2030)", which aims to enhance the supply chain and technological advancements in the industry [11][12]. - Key performance indicators for major drugs include significant sales growth for Eli Lilly's Tirzepatide, projected to reach $36.5 billion in 2025, and a 54% year-on-year increase in sales for the Alzheimer's drug Lecanemab [14][16]. Market Performance Summary - The Shenwan Pharmaceutical and Biological Index ranked 15th among 31 sub-industries, with various segments showing mixed performance: - Raw materials (+0.6%) - Traditional Chinese medicine (+2.6%) - Chemical preparations (-0.8%) - Blood products (-0.5%) [2][4]. - The overall valuation of the pharmaceutical sector stands at 29.6 times earnings, ranking 13th among 31 primary industries [4][2]. Recent Key Events - The report highlights several significant collaborations and licensing agreements, including: - A $1.5 billion deal between Saint Inbiotech and Genentech for RNAi therapy [17]. - A $1 billion commercialization agreement for a JAKi nasal spray by Jichuan Pharmaceutical [18]. - A $3.88 billion licensing agreement for PD-1 monoclonal antibody H drug by Fuhong Hanlin with Eisai [19] [20]. - The report also notes the IPO preparation of Brain Interface Company, which aims to innovate in neuro-scientific solutions [21]. Investment Recommendations - The report suggests focusing on companies involved in the high-quality development of traditional Chinese medicine, such as Zhaoli Pharmaceutical, Lingrui Pharmaceutical, and Huaren Jiangzhong [2][11]. - It also recommends innovative drug companies and CXO firms, including Hengrui Medicine, BeiGene, and WuXi AppTec, as potential investment opportunities [2][11].